In primary systemic amyloidosis, small numbers of bone marrow plasma cells secrete monoclonal light chains that form extracellular fibrils (amyloid) in various organs. Evidence limited to a few cases suggests that rare clonal elements can also be found in the peripheral blood (PB), and this may be relevant in PB stem cell autotransplantation. Since up to 40% of amyloid clones do not synthesize heavy chains, in order to detect tumor cells with high specificity and sensitivity we developed a seminested allele-specific oligonucleotide polymerase chain reaction for tumor light chains. Clone-related sequences were detected in DNA and/or cDNA from the PB cells of eight of 10 patients at diagnosis and from apheretic collections of three of four cases undergoing PB progenitor autotransplantation. Since there are experimental data suggesting that circulating tumor cells may be involved in the growth of the amyloidogenic clone and may be chemoresistant, these findings are relevant to the use of leukapheresis purging strategies for PB progenitor autotransplantation in amyloidosis.
Small numbers of indolent monoclonal plasma cells (PC) in the bone marrow are responsible for the secretion of amyloid-forming light chains in primary systemic (AL) amyloidosis. 1 However, analyses limited to a few cases have shown that clonal elements do not seem to be confined to bone marrow but can also circulate in the peripheral blood (PB). 2, 3 The existence of tumor elements outside the bone marrow environment is of biological and clinical importance. Experimental data suggest that these cells may be involved in the growth of the amyloid clone 2 and analogously to myeloma circulating cells, 4 they may be chemoresistant. Reinfusion of tumor cells is of concern in doseintensive therapy with PB stem cell rescue -a promising approach for suitable patients. [5] [6] [7] Correspondence: Dr G Merlini, Biotechnology Research Laboratory, University Hospital-IRCCS Policlinico San Matteo, P le Golgi, 2, 27100 Pavia, Italy Received 6 July 1998; accepted 23 September 1998 To detect tumor cells with high sensitivity and specificity, we developed a seminested allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) for monoclonal light chains (up to 40% of amyloid clones do not synthesize heavy chains), 8 and looked for clonal sequences in DNA and/or cDNA from the PB of 10 amyloidosis patients at diagnosis and in PB stem cell harvests from four of these cases.
Materials and methods

Patients and bone marrow studies
Ten patients with biopsy-proven AL amyloidosis were analyzed. Peripheral blood and bone marrow aspirates were taken after informed consent. Analyses of bone marrow PC light chain / ratios 8 and labeling indexes 9 were performed by immunofluorescence procedures. Monoclonal components were detected through immunofixation of serum and urine using anti-isotype-specific rabbit antisera (Dako, Glostrup, Denmark).
Cloning and sequencing of amyloidogenic light chains
Isolation of the amyloidogenic light chain variable (VL) regions was obtained by an inverse PCR-based procedure recently described in detail. 10 Briefly, double-stranded cDNA from Ficoll separated bone marrow mononuclear cells was blunt-ended, ligated upon itself to form a circle using T4 DNA ligase (GIBCO-BRL, Grand Island, NY, USA), PCR-amplified with primers specific for the 5Ј and 3Ј ends of the heavy and light chain constant region isotypes and oriented toward the V region or towards the 3Ј end of the constant regions, respectively. The PCR products were gel-purified and subcloned using the TA cloning kit (Invitrogen, Carlsbad, CA, USA). Several plasmid inserts were then sequenced on either strand using an automated DNA sequencer 10 and compared to each other. The presence of the same V region sequence in multiple clones indicates its monoclonal origin. 10, 11 ASO-PCR DNA and RNA were extracted from mononuclear cells using TRIZOL (GIBCO-BRL). Three oligonucleotides (18 mer) designed on the patient's monoclonal light chain CDR1 (oligo CDR1) and CDR3 (oligo CDR3, specific for the V-J junction; oligo CDR3 nested, specific for the 3Ј end of the V segment) were employed in a seminested procedure ( Figure 1 ). To maximize tumor specificity, primers were designed in somatically mutated areas 11 identified by sequence comparison with the most homologous germline gene present in the databases EMBL-GenBank and V-BASE (V BASE Sequence Directory, Tomlinson et al, MRC Centre for Protein Engineering, Cambridge, UK).
One microgram of DNA was used for amplification. RNA was employed (ASO-RT-PCR) when DNA amplification was negative. In the latter case, 1 g of total RNA was retrotranscribed in a final volume of 20 l containing 200 units SuperScript II RT, 0.5 g oligo dT (both from GIBCO-BRL), 2 l 0.1 M DTT, 4 l 5 ϫ first strand buffer (250 mm Tris-HCl pH 8.3, 375 mm KCl, 15 mm MgCl 2 ), 1 l 10 mm dNTP mix; half of the single strand reaction was used for the first amplification. Each PCR round consisted of 30 cycles, with annealing temperatures calculated according to the GC and AT content for each couple of primers. One percent of the first PCR reaction was employed in the second amplification round. Cycling conditions generally consisted of 94°C (40 s), 54°C to 62°C (40 s), 72°C (1 min). A final extension step at 72°C (15 min) was applied. 0.2 units of DyNazyme I thermostable DNA polymerase (Finnzymes Oy, Espoo, Finland) were used in a final volume of 50 l consisting of 1 ϫ PCR buffer (10 mm Tris-HCl pH ϭ 8.8, 1.5 mm MgCl 2 , 50 mm KCl, 0.1% Triton X-100), 200 nm dNTP mixture, 7.5 pmoles of primers. The seminested PCR products were run on 1.5% agarose gel in TBE and visualized by staining with ethidium bromide. Direct automated sequencing 10 was used to confirm the identity of the amplified products. To estimate the sensitivity of the procedure, bone marrow DNA and total RNA from a normal subject and from a patient with 10% (10 Ϫ1 ) PC infiltration were adjusted at the same concentration. The tumor nucleic acid was serially 10-fold diluted (from 10 Ϫ2 to 10
Ϫ7
) in the relative normal nucleic acid and 1 g of the mixture was used as the starting material. 
Results
The clinical characteristics and laboratory values of the 10 patients with AL amyloidosis are reported in Table 1 . An expansion of monotypic PC was detected by bone marrow light chain / ratio analysis in all but one case, patient SAR (Table 1) , who had an IgM monoclonal gammopathy with minimal marrow infiltration, as shown by the normal values of lymphocyte (1.4) and PC light chain ratios (Table  1) analyzed on four different occasions. As is typically found in AL amyloidosis, 12 PC in S-phase of the cell cycle (PC labeling indexes) were extremely rare. There was no evidence of associated multiple myeloma.
The sequences of most amyloidogenic VL regions were available.
11 SAR, TAS and SCH monoclonal light chains were isolated following the same cloning procedures. VL regions belonged to different V families (SAR: VVI; TAS and SCH: VIII) and showed various degrees of somatic mutations clustered in the CDR regions (data not shown). Figure 1 illustrates the two-step ASO-PCR strategy employed for the detection of clonal sequences. DNA or first strand cDNA can be used as the starting material. (ASO-RT-PCR) normal cells could be detected. Of course, it is to be expected that the sensitivity of ASO-PCR may vary slightly according to the primers and, in the case of RT-PCR, according to the RNA tumor cell content. Table 2 summarizes the results of ASO-PCR conducted on patients' bone marrow (as positive control) and on peripheral blood mononuclear cells. Amplification was obtained from circulating cells in eight of 10 patients. In three cases (Table 2 ; PB from FIL and SCH, bone marrow from patient SAR) only the cDNA approach was successful. Sequencing confirmed the monoclonal nature of the PCR products. Representative ASO-PCR amplifications from PB cells are reported in Figure 3a (lanes 3 to 8) . The use of three patient-specific oligonucleotides simplified optimization of the stringency conditions and a single, discrete amplification signal was obtained by utilizing the calculated melting temperatures of the primers (Figure 3) . Table 2 Results of ASO-PCR analysis of bone marrow, peripheral blood mononuclear cells and leukaphereses of AL amyloidosis patients Results of the analyses conducted on leukaphereses from the four patients undergoing autologous PB stem cell transplantation are included in Table 2 . Collections were harvested after cyclophosphamide (4 g/m 2 ) and rhG-CSF (5 g/kg/day) (SAR, PAP) or rhG-CSF alone (TAS, FER). All the preparations tested from patients TAS, FER and PAP, whose PB was positive for clonal elements at diagnosis, were found to be contaminated (examples are shown in Figure 3b, lanes 3 to 6) ; by contrast, SAR was repeatedly negative, both in PB and in the apheretic materials (Table  2 and Figure 3b, lane 7) .
Discussion
Using a sensitive clone-specific PCR we provided indirect evidence that tumor elements are present in the peripheral blood and apheretic products of most previously untreated amyloidosis patients.
Amyloid V regions were isolated by an inverse PCRbased procedure characterized by universal amplification of complete V regions. 10 The general applicability of this approach is illustrated by the successful cloning of monoclonal light and/or heavy chains in a series of 24 consecutive patients 10, 11 (this report and unpublished results). Since the complete sequence of the V region is obtained, tumorspecific information is extended, and this was exploited to set up a seminested PCR employing primers designed on the light chain CDR1 and CDR3, the areas of greatest nucleotide variation in amyloid V regions. 11 This technique matched the tumor cell detection capacity of a recently described heavy chain-based nested approach 13 and is suitable for identifying rare neoplastic cells, as for example in an analysis of tumor purging from transplant material or of minimal residual disease. The rationale behind the use of ASO-PCR for residual clonal cell detection lies in the finding that apparently all amyloid PCs from the same patient express identical light chain V regions, ie there is no significant intraclonal somatic mutation diversification. 11 The application of the seminested strategy is not confined to primary amyloidosis or to other conditions characterized by exclusive secretion of free light chains, such as micromolecular myeloma, but can be successfully extended to the amplification of tumor heavy chain V regions with similar sensitivity (unpublished results).
Clonal V region sequences were detected in the peripheral blood of 8/10 cases. In two patients, the more sensitive cDNA approach was necessary, suggesting that tumor cell numbers can be very low in some instances.
Leukaphereses repeatedly revealed the presence of clonotypic sequences in three of four cases. Recently, Comenzo et al 14 showed that collections from four of seven amyloid patients mobilized with high-dose rhG-CSF were tumor contaminated at a single-round RT-PCR analysis. Peripheral blood cells before treatment were not evaluated, and the possibility that the growth factor might have favored mobilization of tumor cells from bone marrow [15] [16] [17] could not be excluded. Our results demonstrate that clonal cells already circulate in the peripheral blood of most amyloidosis patients and that tumor-negative apheretic preparations are not usually obtained if a sensitive tworound ASO-PCR is used; on the other hand, the procedure for CD34 ϩ cell collection apparently did not favor tumor cell mobilization in the patient whose PB was PCR negative at diagnosis (patient SAR, Table 2 ).
It is possible that a few marrow PC that spilled into PB may have contributed to a positive PCR result. However, in our previous work, idiotype-positive elements with morphological and immunophenotypical features of mature B lymphocytes were identified in the peripheral blood of amyloidosis patients at diagnosis, whereas circulating clonal PC were undetectable.
2 Clone-related B cells differentiated in vitro to PC, and marrow elements at pre-PC differentiation stages were also identified. 2 We suggested that, by analogy to multiple myeloma, [18] [19] [20] circulating clonal B cells represent the precursors responsible for bone marrow PC accumulation and axial dissemination. Since amyloid clonal lymphocytes are resting, 2 they might manifest poor sensitivity to chemotherapy. Indeed, sequential ASO-PCR analysis of myeloma peripheral blood clonal cells after stem cell transplant has demonstrated that this compartment is only minimally altered by intensive chemotherapy, 21 and it is hypothesized that this cell population may be an important contributor to myeloma relapse. 4, 21, 22 Recurrences of clonal PC disorders have also been observed in some amyloid patients who achieved complete clinical remission following dose-intensive therapy, 7 so it is possible that reinfusion of tumor cells may have played a role. Myeloma and amyloidosis circulating B cells express surface CD22 23 and amyloid B cells are CD34 negative. 2 These features suggest the possibility of treating patients or stem cell harvests with anti-CD22 immunotoxins, 24, 25 given the sensitivity of circulating tumor cells to the action of these compounds, 23 or the possibility of enriching for CD34 ϩ cells. 14 
